Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The healthcare sector is undergoing significant transformation, as traditional drug development methods merge with cutting-edge gene editing technologies. As a result, investors are faced with a choice between two prominent biotech companies: Axsome Therapeutics (NASDAQ: AXSM) and CRISPR Therapeutics (NASDAQ: CRSP). Axsome specializes in the commercialization of treatments for central nervous system (CNS) disorders, while CRISPR is renowned for its leadership in gene-based medicines, utilizing its proprietary platform for innovation.

Both companies find themselves at pivotal points in their development journeys, presenting investors with distinct risk and reward opportunities within the biotech industry. Axsome Therapeutics is dedicated to developing therapies for various CNS conditions, such as depression, migraine, and narcolepsy. The company currently markets several medications in the United States, including AUVELITY and SUNOSI, which has also gained traction in international markets.

In June 2026, Axsome Therapeutics successfully resolved patent litigation concerning SUNOSI. This resolution had a positive impact on the company's commercial prospects within the biotech sector.

CRISPR Therapeutics, on the other hand, is a pioneer in the field of gene-based medicines. Leveraging its flagship platform, the company is at the forefront of utilizing gene editing technologies to develop novel treatments. As with Axsome, CRISPR Therapeutics is currently navigating critical stages in its development, offering investors a different set of considerations when analyzing potential investments in the biotech landscape.